SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
Netflix Stock Drops After Weak Q3 Outlook Overshadows Mixed Q2 Earnings 
Tesla Stock Outlook: Strong EV Sales Boost Earnings, but AI Projects Drive Long-Term Value 
TSMC Sees Multi-Year AI Chip Demand as Arizona Expansion Reaches $265 Billion 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
PayPal Rejects $53 Billion Stripe-Advent Takeover Offer as Too Low: Report 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
ASML Trillion-Dollar Valuation: Can Europe’s AI Chip Giant Reach the Historic Milestone? 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Nationwide Data Center Protests Highlight Growing Backlash Against AI Expansion 
Samsung Electronics America to Cut 739 New Jersey Jobs as Texas Headquarters Move Advances 
SpaceX Targets Thursday Launch for Starship's 13th Test Flight After Last-Minute Delay 
Why Maruti Suzuki Is Losing Market Share in India as SUVs and Premium Features Gain Popularity 
AbbVie pharmaceutical company announced on Wednesday, Dec. 6, that it will buy Cerevel Therapeutics. This deal is the company's latest attempt to expand its drug pipeline, as its best-selling treatments are currently facing generic competition.
Share Prices Soar with the Buyout Deal
According to CNBC, the share prices of Cerevel Therapeutics shot up to 16% at the close on Wednesday. This is equivalent to almost $43 per share, just a little below the purchase price of over $8 billion.
On the other hand, AbbVie's were said to have slightly gone down by less than 1% in the extended trading. These changes in the share prices show that the acquisition negotiations between the companies have a slight effect on their value.
Agreed Terms of the Deal
AbbVie said that under the agreed terms of the transaction, it will buy all the outstanding shares of Cerevel Therapeutics for the price of $45.00 per share, which will be paid in cash. The deal values the neuroscience drugmaker at about $8.7 billion.
It was mentioned that the companies' respective boards of directors have already greenlighted the deal. This transaction is expected to be completed by mid-2024, subject to regulatory approvals, Cerevel shareholders' approval, and other customary closing conditions.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," AbbVie's chairman and chief executive officer, Richard A. Gonzalez, said in a press release. "AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets."
Ron Renaud, Crevel Therapeutics' president and chief executive officer, commented, "Cerevel has always been committed to transforming what is possible in neuroscience. With AbbVie's long-standing expertise in developing and commercializing medicines on a global scale, Cerevel's novel therapies will be well positioned to reach more people living with neuroscience diseases."
Photo by: Abbvie Media Resources
